Positive impactResults
Glenmark Pharma shares will react to better-than-expected US sales in Q2, 14% growth in India biz
CNBC-TV18 1 hr ago·6 Nov 2026, 1:49 am
Glenmark Pharma's shares are likely to see movement following the release of its second-quarter results. The company reported a significant turnaround in its domestic business, with revenue growing by over 700% year-on-year. However, when adjusted for the impact of a previous divestment, the core formulation business showed a more moderate growth of around 14%.
For investors, this divergence between total revenue and core growth is a key point of focus. The strong recovery in India suggests that the company is regaining its footing in the domestic market, which is a major revenue driver. The better-than-expected performance in the US segment adds to the positive sentiment surrounding the stock.
Excerpt from CNBC-TV18
Published On Nov 6, 2026 | 07:19 IST Last Updated On Nov 6, 2026 | 07:19 IST Glenmark's India business reported revenue of ₹1,327.4 crore, up 704.2% from ₹165.1 crore in the year-ago quarter. However, on a like-for-like basis, the company's India formulation business recorded year-on-year growth of around 14% in…Read the original at CNBC-TV18
Affected stocks
Bullish1 stock
Bull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.
Key takeaways
- Concerns Glenmark Pharmaceuticals (GLENMARK).
- Category: Results.
- AI reads the tone as positive (potentially bullish) for the stock.
Why it matters
A routine update for Glenmark Pharmaceuticals. The tone is positive — historically associated with upward pressure, though not predictive. Use the price and stock snapshot to gauge how the market is responding.
